632. Chronic Myeloid Leukemia: Therapy— Building The Future CML
Watch Session
45 Nilotinib Vs. Dasatinib in Achieving MR4.5 for Newly Diagnosed Chronic Myeloid Leukemia: Results of the Prospective Randomized Phase 3 Study, JALSG CML212[nbsp]according to ASH clinically relevant abstractItaru Matsumura, Shigeki Ohtake, Yoshiko Atsuta, et al.
46 Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial according to ASH clinically relevant abstract
Tim H Brümmendorf, Jorge E. Cortes, Dragana Milojkovic, et al.
47 Do Not Miss Karyotyping at Chronic Myeloid Leukemia Diagnosis: An Italian Campus CML Study on the Role of Complex Variant Translocations according to ASH clinically relevant abstract
Massimiliano Bonifacio, Chiara Elena, Mariella D'Adda, et al.
Jorge E. Cortes, Jane Apperley, FRCP, FRCPath, Andreas Hochhaus, et al.
49 Mutated Cancer-Related Genes Detected at Diagnosis of CML and a Novel Class of Variant Associated with the Philadelphia Translocation Are Both Independent Predictors of Inferior Outcomes according to ASH clinically relevant abstract
Naranie Shanmuganathan, Carol Wadham, Nur Hezrin Shahrin, et al.
50 Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study according to ASH clinically relevant abstract
Giorgina Specchia, MD1, Patrizia Pregno2*, Massimo Breccia, et al.